Sonoma Pharmaceuticals - SNOA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.25
  • Forecasted Upside: 2,066.67%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.15
▼ -0.01 (-6.25%)

This chart shows the closing price for SNOA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sonoma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNOA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNOA

Analyst Price Target is $3.25
▲ +2,066.67% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Sonoma Pharmaceuticals in the last 3 months. The average price target is $3.25, with a high forecast of $3.25 and a low forecast of $3.25. The average price target represents a 2,066.67% upside from the last price of $0.15.

This chart shows the closing price for SNOA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Sonoma Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/5/2023LADENBURG THALM/SH SHInitiated CoverageBuy$3.25Low
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/23/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/21/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Sonoma Pharmaceuticals logo
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Read More

Today's Range

Now: $0.15
Low: $0.15
High: $0.16

50 Day Range

MA: $0.15
Low: $0.13
High: $0.18

52 Week Range

Now: $0.15
Low: $0.12
High: $1.52

Volume

166,177 shs

Average Volume

1,697,902 shs

Market Capitalization

$2.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Sonoma Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Sonoma Pharmaceuticals in the last twelve months: LADENBURG THALM/SH SH.
View the latest analyst ratings for SNOA.

What is the current price target for Sonoma Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Sonoma Pharmaceuticals in the last year. Their average twelve-month price target is $3.25, suggesting a possible upside of 2,066.7%. LADENBURG THALM/SH SH has the highest price target set, predicting SNOA will reach $3.25 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $3.25 for Sonoma Pharmaceuticals in the next year.
View the latest price targets for SNOA.

What is the current consensus analyst rating for Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNOA will outperform the market and that investors should add to their positions of Sonoma Pharmaceuticals.
View the latest ratings for SNOA.

What other companies compete with Sonoma Pharmaceuticals?

How do I contact Sonoma Pharmaceuticals' investor relations team?

Sonoma Pharmaceuticals' physical mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The company's listed phone number is (800) 759-9305 and its investor relations email address is [email protected]. The official website for Sonoma Pharmaceuticals is www.sonomapharma.com. Learn More about contacing Sonoma Pharmaceuticals investor relations.